HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?

Affiliations

Comment

Tatiana Ignatova et al. Ann Rheum Dis. 2014 Sep.

. 2014 Sep;73(9):e58.

doi: 10.1136/annrheumdis-2014-205997. Epub 2014 Jun 12.

¹ Clinic of Nephrology, Internal and Occupational Diseases, First Moscow State Medical University, Moscow, Russia.

No abstract available

Keywords: DMARDs (biologic); Infections; Systemic vasculitis.

Comment in

HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al.
Saadoun D, Cacoub P. Saadoun D, et al. Ann Rheum Dis. 2014 Sep;73(9):e59. doi: 10.1136/annrheumdis-2014-206022. Epub 2014 Jun 26. Ann Rheum Dis. 2014. PMID: 24969272 No abstract available.

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Saadoun D, et al. Ann Rheum Dis. 2014 May;73(5):831-7. doi: 10.1136/annrheumdis-2012-202770. Epub 2013 Apr 20. Ann Rheum Dis. 2014. PMID: 23606708 Free PMC article. Clinical Trial.